We are live on
!
Find out more
ACP
Acuta Capital Partners Portfolio holdings
AUM
$143M
1-Year Est. Return
773.18%
This Fund
S&P 500
This Quarter
Est. Return
+12.78%
1 Year Est. Return
+773.18%
3 Year Est. Return
+7,269.42%
5 Year Est. Return
+14,284.66%
10 Year Est. Return
+1,769,765.59%
AUM
$208M
AUM Growth
+$29.3M
(+16%)
Cap. Flow
+$21.6M
Cap. Flow
% of AUM
10.36%
Top 10 Holdings %
Top 10 Hldgs %
53.69%
Holding
72
New
35
Increased
16
Reduced
9
Closed
7
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
BioMarin Pharmaceuticals
BMRN
|
+$5.44M |
| 2 |
DERM
Dermira, Inc.
DERM
|
+$4.69M |
| 3 |
Iovance Biotherapeutics
IOVA
|
+$4.6M |
| 4 |
IRIDEX
IRIX
|
+$4.41M |
| 5 |
Acadia Pharmaceuticals
ACAD
|
+$2.88M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
FOLD
Amicus Therapeutics
FOLD
|
+$9.36M |
| 2 |
CYNA
CYNAPSUS THERAPEUTICS INC COM PAR NO PAR (CANADA)
CYNA
|
+$6.39M |
| 3 |
CPXX
CELATOR PHARMACEUTICALS INC. COMMON STOCK
CPXX
|
+$5.51M |
| 4 |
SBBP
Strongbridge Biopharma plc.
SBBP
|
+$4.51M |
| 5 |
IMMU
Immunomedics Inc
IMMU
|
+$4.43M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 85.25% |
| 2 | Miscellaneous | 13.07% |
| 3 | Technology | 1.68% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Insmed
INSM
$27.1B
| $2.17M | 1.04% |
+220,000
| New | +$2.57M |
|
27
Pacific Biosciences
PACB
$429M
| $2.11M | 1.01% |
300,000
+134,632
| +81% | +$1.23M |
|
|
AGN
28
DELISTED
Allergan plc
AGN
| $1.96M | 0.94% |
+8,500
| New | +$1.96M |
|
|
CYNA
29
DELISTED
CYNAPSUS THERAPEUTICS INC COM PAR NO PAR (CANADA)
CYNA
| $1.93M | 0.93% |
115,400
-475,130
| -80% | -$6.39M |
|
30
Neurocrine Biosciences
NBIX
$15.4B
| $1.91M | 0.92% |
+42,000
| New | +$1.93M |
|
|
PGNX
31
DELISTED
Progenics Pharmaceuticals Inc
PGNX
| $1.89M | 0.91% |
448,885
+216,085
| +93% | +$1.04M |
|
32
Travere Therapeutics
TVTX
$6.1B
| $1.76M | 0.85% |
98,788
-101,212
| -51% | -$1.64M |
|
|
EPIX
33
DELISTED
ESSA Pharma
EPIX
| $1.75M | 0.84% |
28,512
+5,145
| +22% | +$321K |
|
34
Rigel Pharmaceuticals
RIGL
$856M
| $1.67M | 0.8% |
74,775
-2,909
| -4% | -$72.3K |
|
35
AtriCure
ATRC
$3.01B
| $1.6M | 0.77% |
+112,923
| New | +$1.72M |
|
36
CALL
Sarepta Therapeutics
SRPT
$2.18B
| $1.53M | 0.73% |
+80,000
| New | +$1.48M |
|
|
WBMD
37
DELISTED
WebMD Health Corp.
WBMD
| $1.45M | 0.7% |
+25,000
| New | +$1.56M |
|
38
Cytokinetics
CYTK
$9.72B
| $1.34M | 0.64% |
+140,969
| New | +$1.16M |
|
|
SGY
39
PUT
DELISTED
Stone Energy
SGY
| $1.3M | 0.63% |
+19,026
| New | +$761K |
|
|
GHDX
40
DELISTED
Genomic Health, Inc.
GHDX
| $1.26M | 0.61% |
+48,800
| New | +$1.3M |
|
41
Assembly Biosciences
ASMB
$516M
| $1.25M | 0.6% |
+18,787
| New | +$1.23M |
|
|
RXDX
42
DELISTED
Ignyta, Inc.
RXDX
| $1.25M | 0.6% |
+229,748
| New | +$1.53M |
|
|
ALIM
43
DELISTED
Alimera Sciences
ALIM
| $1.2M | 0.58% |
64,955
| – | – |
|
44
Universal Display
OLED
$3.55B
| $1.02M | 0.49% |
15,000
-55,000
| -79% | -$3.38M |
|
|
RPTP
45
DELISTED
RAPTOR PHARMACEUTICAL CORP COM STK (DE)
RPTP
| $938K | 0.45% |
+174,708
| New | +$896K |
|
46
Outlook Therapeutics
OTLK
$166M
| $828K | 0.4% |
+1,521
| New | +$907K |
|
|
SVA
47
DELISTED
Sinovac Biotech, Ltd
SVA
| $786K | 0.38% |
+132,503
| New | +$812K |
|
|
MRTX
48
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $683K | 0.33% |
125,000
+21,717
| +21% | +$346K |
|
49
Ironwood Pharmaceuticals
IRWD
$699M
| $654K | 0.31% |
+59,700
| New | +$583K |
|
|
BEAT
50
DELISTED
BioTelemetry, Inc.
BEAT
| $564K | 0.27% |
+34,630
| New | +$509K |
|
Similar funds
FPC
WWM
AVA
BOM
PWM
FF
JPT
BJF
Acuta Capital Partners's Q2 2016 Portfolio in Review
As of Q2 2016, Acuta Capital Partners held 72 positions worth $208M, up 16% from $179M the previous quarter. Its ten largest holdings account for 54% of the portfolio.
Acuta Capital Partners deployed $21.6M of net new capital in Q2 2016, opening 35 new positions and adding to 16 existing holdings. Its largest new stake was BioMarin Pharmaceuticals: 64,000 shares worth $4.98M.
By sector, the portfolio is most concentrated in Healthcare at 85% of assets, up from 79% a quarter earlier, followed by Miscellaneous and Technology.
On the sell side, the largest reduction was Amicus Therapeutics, an estimated $9.36M trimmed.
- Acuta Capital Partners's largest Q2 2016 buy was BioMarin Pharmaceuticals: 64,000 shares worth $4.98M.
- Acuta Capital Partners added most to Iovance Biotherapeutics in Q2 2016, an estimated $4.6M increase.
- Acuta Capital Partners's biggest Q2 2016 reduction was Amicus Therapeutics, cutting an estimated $9.36M.
- Acuta Capital Partners fully exited CELATOR PHARMACEUTICALS INC. COMMON STOCK in Q2 2016, selling an estimated $5.51M.
- Acuta Capital Partners's ten largest holdings make up 54% of its $208M portfolio in Q2 2016.
- Acuta Capital Partners opened 35 new positions and closed 7 in Q2 2016.
- Acuta Capital Partners's portfolio value rose 16% quarter-over-quarter to $208M.
Based on Acuta Capital Partners's 13F filing for Q2 2016, filed 15 Aug 2016.